CBS 2019
CBSMD教育中心
中 文

Acute Coronary Syndrom

Abstract

Recommended Article

Changes in One-Year Mortality in Elderly Patients Admitted with Acute Myocardial Infarction in Relation with Early Management Decade-Long Trends (2001 to 2011) in the Use of Evidence-Based Medical Therapies at the Time of Hospital Discharge for Patients Surviving Acute Myocardial Infarction Prevalence of Coronary Vasospasm Using Coronary Reactivity Testing in Patients With Spontaneous Coronary Artery Dissection Prognostic Value of the Residual SYNTAX Score After Functionally Complete Revascularization in ACS Non-eligibility for reperfusion therapy in patients presenting with ST-segment elevation myocardial infarction: Contemporary insights from the National Cardiovascular Data Registry (NCDR) 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes: The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC) Complete Revascularization with Multivessel PCI for Myocardial Infarction Mortality and morbidity in acutely ill adults treated with liberal versus conservative oxygen therapy (IOTA): a systematic review and meta-analysis
|<<... 12 13 14 15 16 17 18 ...>>|

Original Research2020 Jul 15;S0167-5273(20)33449-5.

JOURNAL：Int J Cardiol. Article Link

The prognostic role of mid-range ejection fraction in ST-segment elevation myocardial infarction

M Alkhalil, A Kearney, D MacElhatton et al. Keywords: mid-range ejection fraction; STEMI; suboptimal medical therapy; renal dysfunction

ABSTRACT

OBJECIVE - There is a paucity of studies investigating the impact of mid-range ejection fraction (mrEF) on clinical outcomes, including ventricular arrhythmias, in ST-segment-elevation myocardial infarction (STEMI). We sought to investigate the prognostic role of mrEF post STEMI and whether recommended medical therapy may modify future risk.


METHODS - 533 consecutive patients from a single large-volume centre who underwent primary percutaneous coronary intervention were included. Reduced EF (<40%), mrEF (40-49%) and preserved EF (≥50%) were defined according to the European Society of Cardiology guidelines. Clinical outcomes were prospectively collected, and the primary endpoint was defined as the composite of death, re-admission with heart failure, sustained ventricular arrhythmia requiring hospitalisation or implantable cardioverter defibrillator over three years follow-up.


RESULTS - There was a stepwise increase in the primary endpoint according to EF group (8%, 17%, 30%, P < .001), which was derived from each individual component. Compared to preserved EF, patients with mrEF had significantly higher risk [HR 4.08 (95%CI 2.38 to 6.99), P < .001]. The use of suboptimal medical therapy was associated with increased future risk, particularly in mrEF [HR 2.62, (95%CI 1.18 to 5.83), P = .018]. The proportion of mrEF patients who experience the primary endpoint was significantly different according the status of kidney function and recommended medical therapy (8%, 20%, 33%, 50%, P < .001).


CONCLUSIONS - Patients presenting with mrEF following STEMI had increased risk of death, heart failure hospitalisation and ventricular arrhythmias compared to preserved EF. Suboptimal medical therapy in mrEF was associated with increased adverse events, particularly in patients with renal dysfunction.


Copyright © 2020. Published by Elsevier B.V.

>CBS CBS 2019

> CBS 2019 REGISTRATION

> CBS 2019 PROGRAM

> CBS 2019 CALL FOR SCIENCE

> CBS 2019 SPOTLIGHTS

 CBSMD

> CBSMD WEBSITE REGISTRATION

> EDUCATION CENTER

> RECOMMANDED PAPER

> TOP 10 RESEARCH PAPER

> PRE-READING

CBS 2019 CBS 2019 FACULTY Education Resource CBSMD Scientific Library
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top